Precision NanoSystems to Present at the 39th Annual Meeting & Exposition of the Controlled Release Society, July 15-18, 2012

Press Release

July 20, 2012

Precision NanoSystems, a provider of innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research, has been selected to present as part of the Soapbox Sessions at the Controlled Release Society (CRS) 39th Annual Meeting & Exposition that will take place at the Centre des congress de Québec, Québec City, Canada from the 15-18 July, 2012.

The CRS Soapbox Sessions introduce the latest, most novel technologies, products and services for delivery science. Euan Ramsay, COO, Precision NanoSystems will describe the NanoAssemblr manufacturing platform for the production of next-generation lipid nanoparticles during Session III on Sunday, July 15, 2012 from 2.30 PM – 3:10 PM.

About Precision NanoSystems, Inc.

At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.


IN THE NEWS

News Article

Vancouver-based biotech firm Precision NanoSystems Inc. (PNI) has created a tabletop device that produces “self-assembling” molecules that carry drugs and gene therapies directly into the cells of the human body. Using the unique physic...

Read More


Press Release

eTheRNA Immunotherapies NV (eTheRNA) and Precision NanoSystems Inc. (PNI) have signed a license and supply agreement for the development and manufacture of immunotherapies by eTheRNA using its proprietary mRNA TriMix platform. PNI’s Clinical Solutions team supported eTheRNA...
Read More